ANTIGON
Timeline
19 events since 2016Board
Capital
Filings
Financial
Insolvency
201620182020202220242026
2025
Bankruptcy closure (by liquidation) Enterprise Court of Hainaut, Charleroi division · judgment of 15-07-2025
2023
Bankruptcy published Enterprise Court of Hainaut, Charleroi division · judgment of 06-02-2023
2022
5 directors reappointedBT LIFE SCIENCE SRL, PHARBIOMED SRL, SAMBRINVEST SPIN-OFF/SPIN-OUT, THEODORUS III and Terry MORO · Permanent representatives: Thierry BALTUS, Hanane EL KENZ, Helena POZIOS and EEBIC venture SA9 points ▸
- Director reappointment, BT LIFE SCIENCE SRL
- Director reappointment, PHARBIOMED SRL
- Director reappointment, SAMBRINVEST SPIN-OFF/SPIN-OUT
- Director reappointment, THEODORUS III
- Director reappointment, Terry MORO
- Permanent representative, Thierry BALTUS
- Permanent representative, Hanane EL KENZ
- Permanent representative, Helena POZIOS
- Permanent representative, EEBIC venture SA
- The deed holds 1 more point.
Judicial reorganisation opened Enterprise Court of Hainaut · amicable agreement · judgment of 02-08-2022
Annual accounts 2021 filed PDFfull format · 17 days before the deadline
2021
Weakest financial year net -€699,512 The net result drops to -€699,512, the lowest from 2017 to 2021.
Annual accounts 2020 filed PDFfull format · 37 days late
Capital increase of €745,000 to €3,272,637.50Capital from €2,527,637.50 to €3,272,637.50, 14,900 new shares · General meeting of 13-07-20213 points ▸
- General meeting, 13-07-2021
- Capital increase, €745,000
- Amendment of the articles, article 5
- The deed holds 1 more point.
2020
Equity above €1m equity €1.7m ▲83.8% Equity rises from €912,051 to €1.7m.
1 director appointedThomas Lienard SRL · Permanent representatives: Thomas Lienard, Marie Bouilez, Alexandre Jouve and Thierry Baltus · General meeting of 26-06-20206 points ▸
- General meeting, 26-06-2020
- Director appointment, Thomas Lienard SRL
- Permanent representative, Thomas Lienard
- Permanent representative, Marie Bouilez
- Permanent representative, Alexandre Jouve
- Permanent representative, Thierry Baltus
- The deed holds 1 more point.
Annual accounts 2019 filed PDFfull format · 27 days late
Capital increase of €1,025,000 to €2,527,637.50Capital from €1,502,637.50 to €2,527,637.50, 20,500 new shares · General meeting of 12-03-20204 points ▸
- General meeting, 12-03-2020
- Capital increase, €1,025,000
- Amendment of the articles, article 5
- Capital, €2,527,637.50
- The deed holds 7 more points.
Permanent representatives: Engel Carsten and Helena PoziosGeneral meeting of 18-11-20193 points ▸
- General meeting, 18-11-2019
- Permanent representative, Engel Carsten
- Permanent representative, Helena Pozios
2019
Capital increase · Amendment of the articlesCapital from €786,375 to €1,502,625, 14,325 new shares · Capital from €1,502,625 to €1,502,637.50, 1,250 new shares · General meeting of 12-07-20195 points ▸
- General meeting, 12-07-2019
- Capital increase, €716,250
- Capital increase, €12,5
- Amendment of the articles, article 5.1
- Amendment of the articles, article 5.2.2
- The deed holds 4 more points.
Annual accounts 2018 filed PDFfull format · 14 days before the deadline
2018
2 directors appointedPermanent representatives: Thomas Pevenage, Engel Carsten and Thierry Baltus · Alexandre Chau (independent director) and BT LIFE SCIENCE (managing director) · General meeting of 28-06-20186 points ▸
- General meeting, 28-06-2018
- Permanent representative, Thomas Pevenage
- Permanent representative, Engel Carsten
- Director appointment, Alexandre Chau (independent director)
- Director appointment, BT LIFE SCIENCE (managing director)
- Permanent representative, Thierry Baltus
Annual accounts 2017 filed PDFfull format · 14 days before the deadline
2017
Capital increase of €125 to €786,375Capital from €786,250 to €786,375, 12,500 new shares · General meeting of 20-09-20174 points ▸
- General meeting, 20-09-2017
- Capital increase, €125
- Capital, €786,375, 28,225 shares
- Amendment of the articles, article 5
- The deed holds 2 more points.
2016
Incorporation PDF9 publications in the Belgian Official Gazette, the last on 09-12-2022
Financial milestones sit on the financial year-end date, not the filing date.
Sources: Publications in the Belgian Official GazetteFilings with the National Bank
History
The capital was increased 3 times between 2019 and 2021, most recently to €3.3m.123 Total assets went from €996,454 in 2018 to €2.6m in 2021 and headcount from 0.8 full-time equivalents in 2019 to 2.5 in 2021.4 ANTIGON was declared bankrupt on 6 February 2023. The bankruptcy was closed on 15 July 2025.56